Navigation Links
EU Drug Regulator Highlights Depression Danger of Weight-loss Pill

The European drug regulator EMEA said Thursday it had maintained authorisation of weight-loss pill Acomplia in the European Union, but had ordered it to be withheld from people suffering from depression.

A panel of experts from the US Food and Drug Administration concluded in June that the dieting treatment, which can also be used to treat diabetes, was unsafe because it caused suicidal thoughts as a side-effect.

The maker of the drug, French group Sanofi-Aventis, abandoned attempts to win approval for the drug in the United States as a result.

The European Medicines Agency (EMEA) recommended Thursday that Acomplia, also known as Rimonabant, should not be given to patients with depression or those taking anti-depressants because of the risk of psychiatric side-effects.

The agency said that depression was known as the main side-effect of the drug and this had been signalled at the time of its approval in June 2006.

However, the Agency's Committee for Medicinal Products for Human Use (CHMP) had recommended upgrading the warning about depression.

Sanofi-Aventis, the fourth-biggest drug maker in the world, announced afterwards that it had changed its labelling to take into account the EMEA's comments.

The recommendation from the EMEA will be sent to doctors prescribing drugs in the countries where the drug in being sold.


'"/>




Page: 1

Related medicine news :

1. US Regulator Sees No Link Between Tamiflu And Japan Deaths
2. Tumor Suppressor p53s Contradictory Regulatory System
3. A brush with the U.S. Regulators can cost a fortune
4. Cancer-causing Property Of Teflon Leaves US Regulators Concerned
5. Human Complexity Can Be Attributed To Regulatory Sequence
6. Regulators Object Drug Produced from Genetically Engineered Farm Animals
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
10. Drug Regulators Need To Think In Long-Term, Say Charities
11. Regulatory T-cells – Protector or Cause of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... management skills and infrastructure. Most providers, however, are unsure how to move forward, ... Ascend to define a path forward tailored to an organization’s specific needs. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: